Director/PDMR Shareholding

03 April 2019 10:00 BST

Transactions by Persons Discharging Managerial Responsibilities

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 29 March 2019, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Deferred Bonus Plan (AZDBP).

The AZDBP award was granted on 24 March 2016, following the deferral of a portion of each PDMR's annual bonus paid in respect of 2015 performance into Ordinary Shares, and vested on completion of the three-year holding period.

Following the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares changed as detailed in the table below:

PDMR Ordinary Shares acquired under the AZDBP
Pascal Soriot 15,755
Marc Dunoyer 4,838

For tax purposes, the fair market value of an Ordinary Share at vest was 6496 pence, being the closing price on the last trading day preceding the vesting.

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter@AstraZeneca.

Media Relations
Gonzalo Viña UK/Global +44 203 749 5916
Rob Skelding UK/Global +44 203 749 5821
Matt Kent UK/Global +44 203 749 5906
Jennifer Hursit UK/Global +44 203 749 5762
Christina M Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharma - Cardiovascular; Metabolism +44 203 749 5711
Nick Stone BioPharma - Respiratory; Renal +44 203 749 5716
Josie Afolabi Other +44 203 749 5631
Craig Marks Finance; Fixed Income +44 7881 615 764
Jennifer Kretzmann Retail Investors; Corporate Access +44 203 749 5824
US toll-free +1 866 381 72 77

Adrian Kemp Company Secretary

AstraZeneca PLC

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Pascal Soriot
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name AstraZeneca PLC
b) LEI PY6ZZQWO2IZFZC3IOL08
4i Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Identification code Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b) Nature of the transaction Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration.
c) Price(s) and volume(s) Price(s) Volume(s)
0 15,755
d) Aggregated information - Aggregated volume - Price Not applicable - single transaction
e) Date of the transaction 29 March 2019
f) Place of the transaction Outside a trading venue

 

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Marc Dunoyer
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name AstraZeneca PLC
b) LEI PY6ZZQWO2IZFZC3IOL08
4i Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Identification code Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b) Nature of the transaction Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration.
c) Price(s) and volume(s) Price(s) Volume(s)
0 4,838
d) Aggregated information - Aggregated volume - Price Not applicable - single transaction
e) Date of the transaction 29 March 2019
f) Place of the transaction Outside a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links